Message from the CEO
FIMECS specializes in Targeted Protein Degradation (TPD), an innovative modality that enables the development of new therapeutics for target molecules that have been considered difficult to drug. Our mission is to pioneer the next generation of medicines by targeting previously untreatable diseases with cutting-edge TPD technology.
Our proprietary drug discovery platform, RaPPIDS (Rapid Protein Proteolysis Inducer Discovery System), is an efficient and innovative drug discovery system that enables the rapid synthesis and evaluation of a large number of compounds, facilitating the swift identification of potential drug candidates. Furthermore, RaPPIDS enables tissue-specific protein degradation, overcoming one of the major challenges in protein degradation therapy. By selectively degrading target proteins only in specific tissues – rather than throughout the entire body – our approach ensures enhanced safety while maximizing therapeutic efficacy.
Leveraging this breakthrough technology, we are committed to developing treatments for diseases with high unmet medical need, particularly those that are difficult to treat with conventional therapies. At the forefront of the life sciences, we strive to unlock new possibilities and bring innovative treatment options to patients around the world.
“Because it is difficult, we must rise to the challenge.” With this belief, we will continue to push the boundaries of drug discovery, using the power of science to make impossible possible and bring hope to patients and their families around the world.
Chief Executive Officer